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Abstract 
Despite the scale up of the use of combined highly active antiretroviral (ARV) therapy, many HIV-1 infected 
patients are still failing treatment in Kenya. In 2007, the Food Drug and Administration (FDA) approved the use 
of CCR5 antagonists in treatment experienced patients. CCR5 antagonists work by inhibiting the entry of HIV-1 
that uses CCR5 as a coreceptor to gain entry into cells. CCR5 59029 A/G (promoter region—rs1799987) is a 
polymorphism that leads to the upregulation of the expression of the CCR5 protein thereby affecting the rate of 
HIV-1 infection. The use of these CCR5 antagonists in Kenya is limited partly because of minimal data on host 
genetics and coreceptor tropism among HIV-1 infected patients. In this study, we aimed at determining the 
prevalence of CCR5 tropic variants and CCR5 59029AG promoter polymorphism known to influence HIV-1 
infection. We sequenced the V3 region of the env gene and inferred the HIV-1 tropism using clonal model of 
Geno2Pheno algorithm (FPR= 5%).   Also, we assessed the frequency of the CCR5 promoter polymorphisms 
among the patients by sequencing the polymorphic region of the CCR5 promoter. Majority of the patients 
(77.27%) had R5 tropic viruses whereas 22.73% of the study subjects had detectable CCR4 using viruses. The 
frequencies of the CCR5 59029 AA, AG, and GG genotypes were 14 (31.82%), 9 (20.45%) and 21(47.73%), 
respectively. Taken together, these results indicate that CCR5 antagonists could have potential therapeutic 
effects in the clinical management of HIV-1 among the infected patients in Kenya. 
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Background information 
Acquired Immunodeficiency Syndrome (AIDS) is one of the major diseases that is responsible for the loss of 
millions of lives worldwide(Unaids, 2013). HIV, the causative agent of AIDS, uses chemokine receptors 
(cysteine-cysteine receptor 5 [CCR5] and/or cysteine-X-cysteine receptor 4 [CXCR4]) as coreceptors to enter 
CD4 expressing cells(Alkhatib, 2009). CXCR4 utilizing viruses are referred to as R4 tropic whereas CCR5 
tropic viruses are known as R5 tropic viruses. Dual tropic viruses use both CXCR4 and CCR5 coreceptors to 
infect cells.  
To inhibit HIV replication, a number of HIV-1 antiretroviral therapies have been designed(Cohen et al., 2013). 
To date, 29 individual antiretroviral drugs from six drug classes have been approved by the U.S. Food and Drug 
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Administration (FDA) to be used in the treatment of HIV-1 infection, including protease inhibitors (PI), 
nucleoside/nucleotide reverse transcriptase inhibitors (NRTI), nonnucleoside reverse transcriptase inhibitors 
(NNRTI), integrase inhibitors (INI), fusion inhibitors (FI), and entry inhibitors (EI)(World Health Organisation, 
2013). Majority of these classes of ARVs act on the various steps of the virus life cycle except the entry 
inhibitors which targets the inhibition of HIV entry through binding to the coreceptors. Up to date, only 
Maraviroc (CCR5 antagonist) has been approved by Food Drug Administration (FDA) for use as a CCR5 
inhibitor whereas several others are under development(Sayana & Khanlou, 2009). These host-target ARV drugs 
promise a good therapy alternative especially for patients who are failing treatment due to virus resistance. 
Cases of drug resistance among HIV-1 infected patients have been reported in Kenya(Hassan et al., 2013, 2014; 
Kebira & Khamadi, 2011; Kiptoo et al., 2013; Lel, Ngaira, Lihana, & Khamadi, 2014; Sigaloff et al., 2012). 
Although host targeted ARVs are being used elsewhere to counter the effects of drug resistance, their use in 
Kenya is limited partly because there’s minimal data on viral tropism and host genetics. It is highly 
recommended that we determine co-receptor tropism before initiating treatment with host targeted ARVs 
because they have selective effect on viral populations. In this study, we employed genotypic assay to asses 
HIV-1 coreceptor use. Also, we determined the frequency of the CCR5 59029 AG promoter polymorphism that 
is known to affect rate of expression of the CCR5 coreceptors and subsequently influence disease progression.   
 
Methodology 
Study population 
Individual patients aged 22-61 years were enrolled between April and August 2013 from 6 comprehensive 
clinical care facilities in the counties of Homa Bay, Kisumu, Kajiado, Nakuru, Kiambu and Malindi, which 
represented 5 geographical provinces of Kenya. All study subjects provided written informed consent. 
Laboratory Procedures 
Five milliliters of venous blood was drawn into EDTA vacutainer tubes from each patient and centrifuged at 
3000rpm for 10 minutes to separate plasma from cells. Peripheral blood mononuclear cells (PBMCs) were 
obtained from plasma-free blood by lysing the blood with 0.84% ammonium chloride.  
RNA extraction and amplification of the Env gene. 
RNA was extracted from plasma of patients with viral load above 1000 RNA copies/ml using QIAamp Viral 
RNA Mini Kit while DNA was isolated from PBMCs of patients with undetected viral load using QIAamp DNA 
Mini Kit. All protocols were strictly as outlined in manufacturer’s manual. The RNA samples were subjected to 
One-Step RT-PCR amplification, using envelope primers M5- 5’- 
CCAATTCCCATACATTATTGTGCCCCAGCTGG -3’ (forward) and M10-5’- 
CCAATTGTCCCTCATATCTCCTCCTCCAGG -3’ (reverse). PCR conditions were reverse transcription at 
50oC for 30 minutes, denaturation at 95oC for 15 min and 38 PCR cycles of denaturation at 94oC for 30sec; 
annealing for 45sec at 58oC and extension at 72oC for 1min. First-round PCR for DNA template followed similar 
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conditions with exception that the RT step was excluded and HotStar Taq DNA polymerase was used instead of 
RT enzyme. Nested PCR was carried out using HotStar Taq polymerase under conditions similar first round 
PCR with the following exceptions: initial denaturation at 95oC for 5 min; 38 cycles of denaturation at 95oC for 
30s, annealing at 56oC and extension at 68oC for 45s and final extension at 68oC. Primers for nested PCR were 
M3_5’- GTCAGCACAGTACAATGCACACATGG-3’ (forward) and M8_5’- 
CCTTGGATGGGAGGGGCATACATTGC-3’ (reverse). PCR amplification strategy targeted a 546 base pairs 
envelope C2V3 corresponding to nucleotides 6975–7520 on the HIV-1 HXB2. Genomic DNA extraction and 
genotyping of the CCR5 gene 
Genomic DNA was extracted from PBMCs using the QIAmp DNA mini kit (Qiagen, Germany), according to 
the manufacturer’s instructions. The concentration of the isolated genomic DNA was measured using a 
spectrophotometer to check the quality and stored at -20oC until use. The isolated DNA was then amplified by 
polymerase Chain Reaction (PCR). Each PCR reaction had a final volume of 25 µL PCR reaction mixture 
containing 2 µL of DNA of ∼200ng/µL, 0.4mM dNTP mix, 2.0mM MgCl2, 0.75 Units of Amplitaq Gold DNA 
polymerase, 1X Amplitaq Gold buffer, nuclease free water (Applied Biosystems, Foster City, CA, USA) and 0.4 
µM of the forward and reverse primer. The forward and reverse primer sequences used for the amplification of 
polymorphic CCR5 regulatory region were 5- TGGGGTGGGATAGGGGATAC -3 and 5- 
TGTATTGAAGGCGAAAAGAATCAG -3 respectively. Each amplification reaction consisted of an initial 
denaturation of 95oC for 15 minutes, 40 cycles at 95oC for 30 sec, 58oC for 30oC and 72oC for 1 minute and a 
final extension of 72oC for 10 minutes. The CCR5 segment produced using the above mentioned primer was 498 
bp in length. 
The PCR products were then separated using 1.6 % agarose gel stained with ethidium bromide and visualized 
under UV light followed by purification using the Qiagen PCR purification kit. Purified products were 
sequenced using standard Big-dye chain terminator chemistry. 
Sequence assembly and analysis 
Sequences were manually inspected, pairwise aligned within the BioEdit sequence analysis using Clustal W. At 
least 2 reference sequences per subtype were included in the alignment of the HIV-1 env sequences. All the 
CCR5 promoter sequences were also aligned with the reference sequence U95626 using CLUSTALW installed 
in Bioedit software(Hall, 2001). The presence of SNPs was analyzed and heterozygosity determined by manually 
inspecting the chromatograms. For the heterozygous individuals, multi-colored peaks for both alleles were 
observed and were shorter in height than those of homozygous individuals. 
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Ethical statement 
This study commenced after getting approval from the Kenya Medical Research Institute Scientific and Ethical 
Committees SSC No. 2477. Written informed consent was obtained from each participant prior to sample 
collection. 
Statistical Analysis 
Data analysis was carried out using the statistical package for social studies (IBM Corp. Released, 2011) Direct 
gene counting was used to determine the frequencies of the CCR5 genotypes and alleles.  
Results 
Tropism genotyping by Geno2Pheno tool. 
HIV-1 tropism was identified through genotype analysis of the HIV third hypervariable loop (V3) of the env 
gene using Geno2pheno online tool(Sing, Beerenwinkel, & Kaiser, 2005). Since the samples were from 
therapied-patients, a clonal model of false positive rate [FPR] cut off of 5% was used as suggested. Also, to 
minimize the number of false predictions of CXCR4 tropic sequences as CCR5 tropic, tropism was inferred 
using 11/12 rule to predict an CXCR4 tropic sequence otherwise they were considered R5 tropic virus. 
Table1: Coreceptors Usage. 
Coreceptor 
Coreceptor Usage 
N (%) 
 
R4 
 
 
R5 
10(22.73%) 
 34(77.27%)  
Table2: CCR5 59029 AG Tropism data. 
GenBank Accession numbers 
The HIV-1 sequences reported in this study have been deposited in the GenBank and assigned the following 
Accession numbers: KM853037- KM853149. 
Prevalence of CCR5-59029 A/G Polymorphism among Kenyans under HAART 
Genotyping of the CCR5 59029 A/G polymorphism was performed in 44 patients infected with HIV. The 
frequencies of the AA, AG, and GG genotypes were found to be 14 (31.82%), 9 (20.45%) and 21(47.73%), 
respectively. 
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 Gender 
N (%) 
Total 
 
     Males Female  
 
   
 
   
CCR5- 59029 Allele    
AA-Homozygous 3 (21.43) 11 (78.57) 14 (31.82) 
GG-Homozygous 4 (44.44) 5(55.56) 9 (20.45) 
AG-Heterozygous 9(42.86) 12(57.14) 21 (47.73) 
 
Table 2: Prevalence of CCR5-59029 A/G Polymorphism among Kenyans under HAART 
Discussion 
CCR5 antagonists are the latest class of antiretroviral drugs that are under development, with maraviroc being 
the only CCR5 antagonist that has been approved by FDA for clinical use. It is necessary that before their use, 
coreceptor usage should be determined. Recently, we established that subtype A viruses are still the predominant 
HIV-1 strains in local circulation in the Kenyan population(Kitawi et al., 2015). To the best of our 
understanding, there is little data on coreceptor usage in a population where HIV-1 subtype A is predominant. In 
this study, sequence of the partial env gene encompassing the V3 region of forty four samples from Kenya was 
analyzed. Subsequently, we estimated the frequency of HIV-1 coreceptors tropism among HIV-1 infected 
patients under HAART. The study population involved treatment experienced Kenyans. Majority of the study 
population (77%) were found to be infected with the R5 tropic viruses, the rest were infected with R4 tropic 
variants. None of the study subjects had a dual infection (R4/R5 tropic variants). These results were consistent 
with other results elsewhere involving HIV-1 non subtype B viruses. We could not however determine whether 
antiretroviral treatment creates an environment for the emergence of CXCR4 tropism.  
We also determined the frequency of CCR5_59029AG polymorphism that is known to influence the rate of 
disease progression. CCR5 59029A/G is an A/G transition at base pair 59029 in the CCR5 promoter that has 
been shown to influence AIDS pathogenesis(Kostrikis et al., 1999). HIV-1 infected individuals with the CCR5-
59029G/G genotype progress more slowly to AIDS than those with the A/A genotype. The frequencies of the 
AA, AG, and GG genotypes were found to be 14 (31.82%), 9 (20.45%) and 21(47.73%), respectively among the 
study subjects. 
To the best of our understanding, this is the first study focusing on the prevalence of HIV-1 tropism among 
therapied-patients in Kenya. These results may therefore assist in the therapy guide among Kenyans living with 
HIV. 
Conclusion 
Our data on the HIV-1 coreceptor tropism in Kenya and the prevalence of CCR5 promoter polymorphism is 
important for therapy planning especially on the use of CCR5 antagonists as options for HIV patients in Kenya. 
The existence of R4 tropic viruses should seriously be considered when decisions are made about regimen 
change for therapy-experienced individuals. This means that HIV-1 coreceptor usage should be screened before 
initiation of any chemokine receptor CCR5 antagonists in therapy experienced Kenyans living with HIV. Also 
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the high frequency of the CCR5GG genotype among HIV-1 infected individuals is noteworthy.  
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